Kevin Winthrop is an Infectious Disease physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3375 SW Terwilliger Blvd
Portland, OR 972394146
Telephone
503-494-7890Registry record last updated 16 Jan 2013.
Clinical trials
- Epetraborole in Patients With Mycobacterium Abscessus Lung Disease
Sponsor: Kevin Winthrop
- Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin
Sponsor: Kevin Winthrop
- RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
Sponsor: RedHill Biopharma Limited
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
37 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech, Inc.Program year202516 payments$63,345openpaymentsdata.cms.gov ↗
- Eli Lilly and CompanyProgram year20254 payments$60,675openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year20259 payments$34,465openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
90%Macrolide Antimicrobial30.4%Azithromycin100%Part D≥49 patientsAntimycobacterial27.7%Ethambutol Hcl100%Part D≥45 patients+ 6 more classes in this area
Respiratory
8.2%beta2-Adrenergic Agonist4.2%Albuterol Sulfate Hfa100%Part D≥21 patientsCorticosteroid4%Trelegy Ellipta100%Part D<11 patientsNervous system
1.8%Gabapentinoids1.8%Gabapentin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2008–2026 per NIH RePORTER. The latest:
- CRISPR detection of circulating cell-free Mycobacterium avium complex (MAC) DNA for rapid diagnosis and monitoring of MAC pulmonary disease
Oregon Health & Science University
FY2026$738,400R01AI177986 - Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Ototoxicity in Patients Receiving Intravenous Amikacin for Treatment of Non-Tuberculous Mycobacterium Infection
Oregon Health & Science University
FY2026$238,311U01DC020175 - Mycobacterium avium complex pulmonary infection: immunologic and transcriptomic signatures of disease and treatment response
Oregon Health & Science University
FY2025$2,335,860R01AI175935
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”